1. Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis
- Author
-
Jiaqu Cui, Yi Miao, Thilo Hackert, Jishu Wei, Xinchun Liu, Thomas Pausch, and Pascal Probst
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030230 surgery ,Cochrane Library ,Gastroenterology ,Pancreaticoduodenectomy ,Pancreatic surgery ,Pancreatic Fistula ,03 medical and health sciences ,chemistry.chemical_compound ,Pancreatectomy ,Postoperative Complications ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Gastric emptying ,business.industry ,Incidence (epidemiology) ,medicine.disease ,Pasireotide ,chemistry ,Pancreatic fistula ,030220 oncology & carcinogenesis ,Meta-analysis ,Surgery ,Somatostatin ,business - Abstract
Pasireotide was recently suggested for the prevention of postoperative pancreatic fistula (POPF) after pancreatic surgery. However, its efficacy remains to be controversially dicussed. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of pasireotide for preventing POPF after pancreatic surgery. A systematic literature search was conducted in PubMed, Web of Science, and The Cochrane Library to identify clinical studies investigating the efficacy of pasireotide after pancreatic surgery. The identified studies were critically appraised, and meta-analyses were then performed. The study was performed in accordance with PRISMA guidelines and was registered at the PROSPERO study database (CRD42018112334). Four studies with a total of 919 patients were included: 418 with pasireotide treatment and 501 controls. Meta-analysis showed that pasireotide could reduce neither clinically relevant POPF rate (OR = 0.78; 95% CI, 0.49–1.24; P = 0.29) nor overall POPF rate (OR = 0.94; 95% CI, 0.60–1.48; P = 0.80) after pancreatic resections. There were no significant differences in delayed gastric emptying, mortality, and postoperative hospital stay after pancreatic surgery. However, pasireotide reduces readmission after pancreatic surgery (OR = 0.61; 95% CI, 0.44–0.85; P = 0.004). Subgroup analyses revealed that prophylactic use of pasireotide did not reduce the incidence of clinically relevant POPF after pancreaticoduodenectomy or distal pancreatectomy compared with the control. Based on the available evidence, use of pasireotide may not reduce clinically relevant POPF as well as it may not improve postoperative course substantially after pancreatic surgery. Further investigator-initiated high-quality trials are needed.
- Published
- 2020
- Full Text
- View/download PDF